"Asked about adoption in the clinic if the drug gains approval, Li said the first step will be to start testing all NSCLC patients for KRAS mutations."
KRAS Inhibitor Continues to Impress in NSCLC
Source : https://www.medpagetoday.com/meetingcoverage/iaslc/90989
More than a third of patients with pretreated non-small cell lung cancer (NSCLC) and a KRAS G12C mutation responded to the investigational agent sotorasib, findings from a phase II study showed.